Outcomes After Different Alternatives for Definitive Treatment Following First Stage Masquelet

Presenting Author(s)

• 

  Kevin Tetsworth, MD, FAAOS, FRACS, FAOrthA, FIOTA

  Staff Specialist
  Queensland Health
  Royal Brisbane Hospital
  Brisbane, Queensland, Australia

  Financial Disclosures: AO Foundation: Paid consultant|Australasian Limb Lengthening and Reconstruction Society (President): Board or committee member|BioBKN: Stock or stock Options|BioConsultancy Pty Ltd: Stock or stock Options|Johnson & Johnson: Paid consultant|Journal of Limb Lengthening and Reconstruction: Editorial or governing board|LifeHealthcare: Paid presenter or speaker|OrthoDx: Stock or stock Options; Unpaid consultant|Orthopaedic Trauma Association: Board or committee member|Smith & Nephew: Paid consultant; Paid presenter or speaker|Stryker: Paid presenter or speaker|

Corresponding Author(s)

• VG

  Vaida Glatt, PhD

  Associate Professor/Director of Basic Science Research
  UT Health San Antonio, Texas, United States

Co-Author(s)

• RB

  Ryan Beattie, MD

  Royal Brisbane Hospital, Brisbane, Australia
• GV

  Gerrit Van De Pol, MD

  Royal Brisbane Hospital